Document Detail

Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes.
MedLine Citation:
PMID:  22918991     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors might be beneficial for the treatment of infections. Our purpose was to examine the association of statin, ACE inhibitor, and angiotensin II receptor blocker (ARB) use with pneumonia-related outcomes.
METHODS: We conducted a retrospective cohort study using Department of Veterans Affairs data of patients aged ≥ 65 years hospitalized with pneumonia. We performed propensity-score matching for 3 medication classes simultaneously.
RESULTS: Of 50119 potentially eligible patients, we matched 11498 cases with 11498 controls. Mortality at 30 days was 13%; 34% used statins, 30% ACE inhibitors, and 4% ARBs. In adjusted models, prior statin use was associated with decreased mortality (odds ratio [OR], 0.74; 95% confidence interval [CI], .68-.82) and mechanical ventilation (OR, 0.81; 95% CI, .70-.94), and inpatient use with decreased mortality (OR, 0.68; 95% CI, .59-.78) and mechanical ventilation (OR, 0.68; 95% CI, .60-.90). Prior (OR, 0.88; 95% CI, .80-.97) and inpatient (OR, 0.58; 95% CI, .48-.69) ACE inhibitor use was associated with decreased mortality. Prior (OR, 0.73; 95% CI, .58-.92) and inpatient ARB use (OR, 0.47; 95% CI, .30-.72) was only associated with decreased mortality. Use of all 3 medications was associated with reduced length of stay.
CONCLUSIONS: Statins, and to a lesser extent ACE inhibitors and ARBs, are associated with improved pneumonia-related outcomes. Prospective cohort and randomized controlled trials are needed to examine potential mechanisms of action and whether acute initiation at the time of presentation with these infections is beneficial.
Eric M Mortensen; Brandy Nakashima; John Cornell; Laurel A Copeland; Mary Jo Pugh; Antonio Anzueto; Chester Good; Marcos I Restrepo; John R Downs; Christopher R Frei; Michael J Fine
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2012-08-23
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  55     ISSN:  1537-6591     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-08     Completed Date:  2013-04-16     Revised Date:  2013-12-05    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1466-73     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin Receptor Antagonists / adverse effects*
Angiotensin-Converting Enzyme Inhibitors / adverse effects*
Cohort Studies
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Odds Ratio
Pneumonia / complications*
Population Surveillance
Retrospective Studies
Grant Support
Reg. No./Substance:
0/Angiotensin Receptor Antagonists; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comment In:
Clin Infect Dis. 2013 Apr;56(8):1193-4   [PMID:  23315319 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The ethics of testing a test: randomized trials of the health impact of diagnostic tests for infecti...
Next Document:  Q Fever: Single-Point Source Outbreak with High Attack Rates and Massive Numbers of Undetected Infec...